Tumour-associated mutant p53 drives the Warburg effect

Nature Communications

Volumn 4, Issue , 2013, Pages

  Zhang, Cen ^a   Liu, Juan ^a   Liang, Yingjian ^a,b   Wu, Rui ^a   Zhao, Yuhan ^a   Hong, Xuehui ^a,b   Lin, Meihua ^a   Yu, Haiyang ^a   Liu, Lianxin ^b   Levine, Arnold J ^c   Hu, Wenwei ^a   Feng, Zhaohui ^a  

^a RUTGERS UNIVERSITY   (United States)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c INSTITUTE FOR ADVANCED STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; PROTEIN KINASE; PROTEIN P53; RHO ASSOCIATED PROTEIN KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

GENE EXPRESSION; INHIBITION; MUTATION; RODENT; TUMOR;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CARCINOGENESIS; CELL ACTIVITY; CELL MEMBRANE; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR CELL; WARBURG EFFECT; WESTERN BLOTTING;

MUS;

ACTINS; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CELLS, CULTURED; GENES, P53; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LACTATES; MALE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION; NEOPLASMS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; WALKER-WARBURG SYNDROME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890695935     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3935     Document Type: Article

References (65)

1. Levine, A. J., Hu, W. & Feng, Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027-1036 (2006).
2. Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413-431 (2009).
3. Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758 (2009).
4. Stambolsky, P. et al. Modulation of the vitamin D3 response by cancerassociated mutant p53. Cancer Cell 17, 273-285 (2010).
5. Muller, P. A. et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-1341 (2009).
6. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat. Cell Biol. 15, 2-8 (2013).
7. Freed-Pastor, W. A. et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244-258 (2012).
8. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004). (Pubitemid 40017691)
9. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004). (Pubitemid 40017690)
10. Feng, Z. & Levine, A. J. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol. 20, 427-434 (2010).
11. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
12. Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nat. Rev. Cancer 9, 691-700 (2009).
13. Levine, A. J. & Puzio-Kuter, A. M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344 (2010).
14. Warburg, O. On the origin of cancer cells. Science 123, 309-314 (1956).
15. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434 (2006). (Pubitemid 43832190)
16. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008). (Pubitemid 351380249)
17. Aylon, Y. & Oren, M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 21, 86-92 (2011).
18. Li, T. et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283 (2012).
19. Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120 (2006). (Pubitemid 44040989)
20. Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650-1653 (2006). (Pubitemid 43902663)
21. Zhang, C. et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl Acad. Sci. USA 108, 16259-16264 (2011).
22. Hu, W. et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl Acad. Sci. USA 107, 7455-7460 (2010).
23. Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49-62 (2012).
24. Fang, S. et al. Corepressor SMRT promotes oxidative phosphorylation in adipose tissue and protects against diet-induced obesity and insulin resistance. Proc. Natl Acad. Sci. USA 108, 3412-3417 (2012).
25. Bogan, J. S. Regulation of glucose transporter translocation in health and diabetes. Annu. Rev. Biochem. 81, 507-532 (2012).
26. Ganapathy, V., Thangaraju, M. & Prasad, P. D. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 121, 29-40 (2009).
27. Szablewski, L. Expression of glucose transporters in cancers. Biochim. Biophys. Acta 1835, 164-169 (2012).
28. Bentley, J. et al. Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface. J. Biol. Chem. 278, 39337-39348 (2003). (Pubitemid 37248489)
29. Ridley, A. J. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 16, 522-529 (2006). (Pubitemid 44444995)
30. Karlsson, R., Pedersen, E. D., Wang, Z. & Brakebusch, C. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 1796, 91-98 (2009).
31. Sahai, E. & Marshall, C. J. RHO-GTPases and cancer. Nat. Rev. Cancer 2, 133-142 (2002).
32. Ishikura, S., Koshkina, A. & Klip, A. Small G proteins in insulin action: Rab and Rho families at the crossroads of signal transduction and GLUT4 vesicle traffic. Acta Physiol. (Oxf) 192, 61-74, 2008). (Pubitemid 350265359)
33. Standaert, M. et al. Comparative effects of GTPgammaS and insulin on the activation of Rho, phosphatidylinositol 3-kinase, and protein kinase N in rat adipocytes. Relationship to glucose transport. J. Biol. Chem. 273, 7470-7477 (1998). (Pubitemid 28152770)
34. Bossi, G. et al. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle 7, 1870-1879 (2008). (Pubitemid 351988754)
35. Muller, P. A., Vousden, K. H. & Norman, J. C. p53 and its mutants in tumor cell migration and invasion. J. Cell Biol. 192, 209-218 (2011).
36. Mizuarai, S., Yamanaka, K. & Kotani, H. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells. Cancer Res. 66, 6319-6326 (2006).
37. Timpson, P. et al. Spatial regulation of RhoA activity during pancreatic cancer cell invasion driven by mutant p53. Cancer Res. 71, 747-757 (2011).
38. Jaffe, A. B. & Hall, A. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269 (2005). (Pubitemid 41740635)
39. Chun, K. H. et al. Regulation of glucose transport by ROCK1 differs from that of ROCK2 and is controlled by actin polymerization. Endocrinology 153, 1649-1662 (2012).
40. Furukawa, N. et al. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab. 2, 119-129 (2005).
41. Lee, D. H. et al. Targeted disruption of ROCK1 causes insulin resistance in vivo. J. Biol. Chem. 284, 11776-11780 (2009).
42. Ishizaki, T. et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol. Pharmacol. 57, 976-983 (2000). (Pubitemid 30253382)
43. Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002). (Pubitemid 37328931)
44. Roberts, P. J. & Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26, 3291-3310 (2007). (Pubitemid 46763022)
45. Wong, K. K., Engelman, J. A. & Cantley, L. C. Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20, 87-90 (2010).
46. Hanel, W. et al. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis. Cell Death Differ. 20, 898-909 (2013).
47. Clemmons, D. R. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature reviews. Drug Discov. 6, 821-833 (2007). (Pubitemid 47500506)
48. Lanzetti, L. Actin in membrane trafficking. Curr. Opin. Cell Biol. 19, 453-458 (2007). (Pubitemid 47268758)
49. Maekawa, M. et al. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285, 895-898 (1999). (Pubitemid 29381991)
50. Wakatsuki, T., Schwab, B., Thompson, N. C. & Elson, E. L. Effects of cytochalasin D and latrunculin B on mechanical properties of cells. J. Cell Sci. 114, 1025-1036 (2001). (Pubitemid 32266272)
51. Goddette, D. W. & Frieden, C. Actin polymerization. The mechanism of action of cytochalasin D. J. Biol. Chem. 261, 15974-15980 (1986). (Pubitemid 17202846)
52. Finley, L. W. et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer cell 19, 416-428 (2011).
53. Weinberg, F. et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc. Natl Acad. Sci. USA 107, 8788-8793 (2010).
54. Freed-Pastor, W. A. & Prives, C. Mutant p53: one name, many proteins. Genes Dev. 26, 1268-1286 (2012).
55. Hu, W., Feng, Z., Teresky, A. K. & Levine, A. J. p53 regulates maternal reproduction through LIF. Nature 450, 721-724 (2007). (Pubitemid 350207678)
56. Haemmerle, G. et al. Defective lipolysis and altered energy metabolism in mice lacking adipose triglyceride lipase. Science 312, 734-737 (2006).
57. Hofmann, S. M. et al. Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice. J. Clin. Invest. 117, 3271-3282 (2007). (Pubitemid 350096984)
58. Koivisto, U. M. et al. Differential regulation of the GLUT-1 and GLUT-4 glucose transport systems by glucose and insulin in L6 muscle cells in culture. J. Biol. Chem. 266, 2615-2621 (1991).
59. Gong, H. et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin 'outside-in' signaling. Science 327, 340-343 (2010).
60. Simpson, I. A. et al. Insulin-stimulated translocation of glucose transporters in the isolated rat adipose cells: characterization of subcellular fractions. Biochim. Biophys. Acta 763, 393-407 (1983). (Pubitemid 14211378)
61. Perrini, S. et al. Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes 53, 41-52 (2004). (Pubitemid 38044696)
62. Michalek, R. D. et al. Estrogen-related receptor-alpha is a metabolic regulator of effector T-cell activation and differentiation. Proc. Natl Acad. Sci. USA 108, 18348-18353 (2011).
63. Wieman, H. L., Wofford, J. A. & Rathmell, J. C. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 18, 1437-1446 (2007). (Pubitemid 46626638)
64. Miyamoto, K., Pasque, V., Jullien, J. & Gurdon, J. B. Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes. Genes Dev. 25, 946-958.
65. Hu, W. et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol. Cell 38, 689-699 (2010).